drugset / Trial / NCT00432237

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

NCT00432237

Phase 3 Completed 1703 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.

Timeline

Start
2007-03
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Telcagepant Small molecule 50 mg Oral
Subject Telcagepant Small molecule 150 mg Oral
Subject Telcagepant Small molecule 300 mg Oral

Indications